May 21, 2018 – Since the Trump administration presented its proposal to lower drug pricing on May 11, both the trade and mainstream media have been discussing whether one provision – a request that the Department of Health & Human Services evaluate the inclusion of drug prices in consumer ads – really has legs. In […]
Read more
By John Kamp, Coalition for Healthcare Communication Executive Director May 16, 2018 — Pharma fared quite well Friday at a White House press briefing outlining ways to reduce drug prices. Indeed, Wall Street responded by increasing the share prices of major drug companies, and even the share prices of payers and insurers, longtime marketing “frenemies.” […]
Read more
May 14, 2018 – President Donald Trump on Friday announced his blueprint to lower drug prices, but his initiatives were deemed “a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks,” by The Wall Street Journal. One of the more controversial items in Trump’s plan is a request that the Department […]
Read more
April 9, 2018 – During a turbulent time in Washington, D.C., healthcare marketers and communication professionals likely have many questions about how the Trump administration’s priorities will impact their industry, how new data privacy regulations that may result from Facebook’s misuse of data will impact their jobs, how a focus on drug pricing could lead […]
Read more
March 26, 2018 – The FDA recently announced the availability of a mobile app, “Drugs@FDA Express,” to provide consumers with an easy way to search for information about FDA-approved brand and generic prescription and over-the-counter drugs and biologics. “Consumers are embracing digital health technologies to inform everyday decisions. From fitness trackers to mobile applications tracking […]
Read more
March 14, 2018 – The FDA has “prioritized a robust social and behavioral science research program” to help the agency understand “how consumers respond to prescription drug promotion,” according to FDA Commissioner Scott Gottlieb, M.D. This Office of Prescription Drug Promotion (OPDP) research “has provided key information to inform our policies related to the proper […]
Read more
Feb. 5, 2018 – A bill to increase price transparency in Oregon, scheduled to be introduced Feb. 5, would require prescription drug manufacturers not only to report drug prices to the state annually, but also would require them to report costs associated with developing and marketing their drugs. If passed, Oregon House Bill 4005 would […]
Read more
Jan. 22, 2018 – The House Energy and Commerce Subcommittee on Health held a markup Jan. 17 that advances H.R. 2026 (http://bit.ly/2G4cRM1), the “Pharmaceutical Information Exchange Act,” which will clarify how drug and medical device companies can share health care economic or scientific information about investigational drugs or devices with payers and formulary committees. “By […]
Read more Dec. 14, 2017 – At a drug pricing hearing held this week by the Senate Health, Education, Labor and Pensions Committee, a representative of the National Academies of Sciences told the panel that the cost of drug advertising must be factored into the price of a drug product, and that Congress should act to end […]
Read more Dec. 4, 2017 – A new report from the National Academies of Science, Engineering and Medicine, “Making Medicines Affordable,” recommends promoting the adoption of industry codes of conduct, eliminating the tax deductibility of advertising expenses and discouraging direct-to-consumer (DTC) advertising in order to lower drug prices (http://bit.ly/2zX0jq7). “In yet another example of drug marketing being […]
Read more